---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Conclusions"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Conclusions. Topics: Summary: conclusions for formulary review. 1 evidence topic quoted from 18 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary/conclusions"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Conclusions

<a id="heading-1.1.4"></a>

## 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

### Summary: conclusions for formulary review

- Regulatory status and timing: palazestrant is investigational, with no FDA-approved indication, prescribing information, or price; Olema Oncology has no product candidates “approved for commercial sale”. FDA granted Fast Track designation in July 2022 for ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. The company anticipates OPERA-01 top-line results in the first quarter of 2027, expects to submit the NDA in 2027, and anticipates potential FDA approval and commercial launch in 2028.
- Pivotal trial: OPERA-01 (NCT06016738) is a phase 3, randomized, open-label trial that, in Part 2, compares palazestrant 90 mg once daily with investigator's choice of standard-of-care endocrine therapy (fulvestrant or an aromatase inhibitor) in participants whose disease progressed after endocrine therapy combined with a CDK4/6 inhibitor. Approximately 510 participants are planned, including 470 for the primary analysis. The dual primary endpoint is PFS by blinded independent central review, analyzed separately in participants with ESR1-mutated tumors and in participants without detectable ESR1 mutations; overall survival is a key secondary endpoint, and patient-reported outcomes (EQ-5D-5L and EORTC QLQ-C30) are secondary endpoints. Enrollment is complete, and no efficacy, safety, or patient-reported outcome results have been reported.
- Monotherapy evidence base: all efficacy data for palazestrant monotherapy come from OP-1250-001 (NCT04505826), an open-label, multicenter phase 1/2 study without a comparator arm, a design the authors state limits interpretation of the safety profile and antitumor activity. These data were obtained with capsules taken in the fasted state, whereas OPERA-01 participants receive a tablet formulation, and only 6 participants were enrolled at the 90 mg dose selected for OPERA-01, all during dose escalation.
- Monotherapy efficacy (OP-1250-001, peer-reviewed publication, data cutoff July 7, 2023): of the 116 participants treated at 60 or 120 mg/day, 95.7% had received a prior CDK4/6 inhibitor and 63.8% at least 2 prior lines of endocrine therapy in the advanced setting. In the 120 mg/day cohort (n = 86), 3 of 66 response-evaluable participants (4.5%) had a confirmed partial response, the CBR was 45.7% (95% CI, 33.7 to 58.1) among 70 CBR-evaluable participants and 58.6% (95% CI, 38.9 to 76.5) among 29 with ESR1 mutations, and median PFS was 4.8 months (95% CI, 3.5 to 7.1) overall and 5.6 months (95% CI, 4.8 to not estimable) with ESR1 mutations. The 60 mg/day cohort had a CBR of 19.2% (95% CI, 6.6 to 39.4) among 26 evaluable participants. The 2023 conference presentation of the 120 mg cohort reports a CBR of 40% (32/81) and a median PFS of 4.6 months.
- Combination evidence comes from two open-label phase 1b studies: with ribociclib (OP-1250-003, July 8, 2025 data cutoff, 72 participants presented, 24 of whom (33%) had no prior line of therapy in the advanced setting), median PFS in the 120 mg cohort was 15.5 months in all participants and 12.2 months in those with a prior CDK4/6 inhibitor, the objective response rate was 34% (15/44) among response-evaluable participants with measurable disease, and median PFS was not reached in the 90 mg cohort at a median follow-up of 10.8 months. With palbociclib (OP-1250-002, September 15, 2023 data cutoff, 46 participants), the CBR was 46% (12/26).
- Safety: in the 120 mg/day monotherapy cohort (n = 86), the most common treatment-emergent adverse events were nausea (62.8%), vomiting (29.1%), and fatigue (25.6%); 8 participants (9.3%) had grade 4 events, including neutropenia in 6, and treatment-related grade 4 neutropenia occurred in 5 (5.8%). Bradycardia (9%) and photopsia (5%) were all grade 1, no QTcF value exceeded 500 ms, and 7 of 116 participants (6.0%) at 60 or 120 mg/day discontinued for adverse events. Ongoing studies monitor blood counts more frequently during the first 6 to 8 weeks. With ribociclib at palazestrant 120 mg, treatment-related neutropenia occurred in 47 of 56 participants (84%), grade 3 in 28 (50%) and grade 4 in 5 (9%), and treatment-related QT prolongation on electrocardiogram in 16 (29%).
- Studied population relative to approved oral endocrine agents: elacestrant, imlunestrant, and vepdegestrant are indicated for ESR1-mutated disease after at least one line of endocrine therapy, and each label directs selection of patients “based on the presence of ESR1 mutation(s)” in a plasma specimen. OPERA-01 enrolls participants “regardless of ESR1 mutation status”, and the company states that “Palazestrant’s approval in ESR1 mutant and wild-type tumors in the 2/3L ER+/HER2- MBC setting would be paradigm-shifting”. Without ESR1 mutations, the PFS hazard ratio for elacestrant was 0.86 (95% CI, 0.63 to 1.19) in an exploratory analysis of 250 participants, and median PFS was 5.6 months with imlunestrant and 5.7 months with standard therapy (hazard ratio 1.00). In OP-1250-001, 51 of 96 participants with baseline circulating tumor DNA results (53.1%) had ESR1 mutations; in the 120 mg cohort, the conference presentation reports a CBR of 32% (12/38) and the 2023 company announcement a median PFS of 3.5 months in participants with ESR1 wild-type tumors.
- Price and economic evidence: no wholesale acquisition cost, budget impact model, or cost-effectiveness analysis of palazestrant has been published. Comparator wholesale acquisition costs are $21,369.00 per 30 tablets of elacestrant 345 mg and $22,500.00 per 56 tablets of imlunestrant 200 mg, and a U.S. third-party payer model estimated an ICER of $8,672,360 per QALY gained for elacestrant compared with standard of care in the overall population. The corporate presentation gives an annual U.S. incidence “estimated at ~40K” alongside “Planning for commercial launch of palazestrant as a monotherapy in 2/3L ER+/HER2- MBC anticipated in 2028”.
- Evidence not yet available for review: OPERA-01 PFS results in the ESR1-mutated and ESR1 mutation-not-detected populations, overall survival, patient-reported outcomes, and safety with the 90 mg tablet in a randomized comparison; FDA-approved prescribing information, including the indicated population; a wholesale acquisition cost; and a budget impact or cost-effectiveness analysis of palazestrant.

Source: [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm); [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm); [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06); [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/); [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738); [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/); [Lin et al. (2023)](https://ir.olema.com/static-files/d0053fca-ac05-4adc-abb4-9c6ba4ec0ae6); [Olema Oncology phase 2 monotherapy results announcement (2023)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-positive-phase-2-monotherapy-clinical); [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97); [ClinicalTrials.gov NCT05508906](https://clinicaltrials.gov/study/NCT05508906); [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf); [Orserdu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217639s007lbl.pdf); [Inluriyo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218881s001lbl.pdf); [Veppanu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219835Orig1s000lbl.pdf); [Jhaveri et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13674379/); [Vermont Attorney General Orserdu report (2023)](https://ago.vermont.gov/sites/ago/files/2023-11/VT-high-cost-prescription-drug-reporting%20Orserdu.pdf); [Eli Lilly and Company Inluriyo WAC disclosure (2025)](https://pricinginfo.lilly.com/assets/pdf/Colorado_WAC_Disclosure_Sheet-Inluriyo.pdf); [Zeng et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10758478/)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
